Результаты поиска

The Rate of Infusion Represents an Important Aspect of Administering Anticancer Agents.

BackgroundInfusion rate is one of the essential elements that should be included in all intravenous orders. Patients may experience adverse consequences or risks associated with inappropriate infusion. Meanwhile, there is growing pressure on the chemotherapy unit to deliver treatment quickly, efficiently, and safely, and thus it is very necessary to improve the chemotherapy process and service to cancer patients. Clinicians should consider how to further standardize infusion therapy, and innovate new infusion strategies to increase efficacy, reduce toxicity, improve patient satisfaction and sa

Совпадение в полном тексте источника
… Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer . 1990;65(4):870–873. doi: 10.1002/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D 19. Cranmer LD, Hess LM, Sugihara T, Muntz HG. … Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol . 2008;134(1):75–82. doi: 10.1007/s00432-007-0250-9 27. Lévy E, Piedbois P; Meta-Analysis Group In Cancer. …

Clinical pharmacology of chemotherapy agents in older people with cancer.

Populations around the world are aging, and the associated increase in cancer incidence has led to the recognition of the importance of geriatric oncology. Chronological age is a poor determinant of pharmacological response to cancer chemotherapy agents. Age-associated changes in physiology and organ function have a significant impact on the clinical pharmacology of cancer chemotherapy agents used in cancer treatment. Altered response to medicines in older people is a consequence of changes in body composition, organ function, concomitant pathophysiology, multiple medications, genetic determin

Совпадение в полном тексте источника
… For example, more attention should be paid to patients with ischemic heart disease when they are treated with fluoropyrimidines as a previous study has demonstrated that patients with a history of cardiac disease, particularly coronary artery disease, were significantly more susceptible to 5-FU cardiotoxicity … The common treatment toxicities of particular concern when caring for older adults with cancer are myelosuppression, mucositis, cardiotoxicity, neurotoxicity, and musculoskeletal side effects [ 52 ]. 4. …

Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital.

Introduction Cancer chemotherapy regimens include multiple classes of adjuvant drugs as supportive therapy. Because of the concurrent intake of other drugs (like antiemetics, antidepressants, analgesics, and antimicrobials), there is a heightened risk for possible QT interval prolongation. There is a dearth of evidence in the literature regarding the usage of QT-prolonging anticancer drugs and associated risk factors that have the propensity to prolong QT interval. The purpose was to explore the extent of the use of QT-interval-prolonging drugs and potential QT-prolonging drug-drug interaction

Совпадение в полном тексте источника
… In this aspect, cardiac arrhythmias can be life-threatening, and rising worry over cancer therapy-related cardiotoxicity has ushered in a new branch of medicine called cardio-oncology [ 2 ]. … Capecitabine cardiotoxicity is common and often expressed with physical effort. Oncologists, cardiologists, and general practitioners should be mindful of this hazard. …

Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.

Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine. Other modalities of TDD are based on new formulations of "old" cytostatic

Совпадение в полном тексте источника
… Liposomes have been primarily studied as anthracycline carriers to reduce the anthracycline-associated cardiotoxicity and increase their therapeutic index [ 73 ]. … Similarly, NPLD did not reduce cardiotoxicity, although cardiac safety signals were elevated in R-CHOP compared to R-COMP in an Austrian randomized phase III study [ 82 ]. So, the cardiotoxicity issue of the liposomal formulations of doxorubicin remains a matter of debate. …

Biomedical Promise of Sustainable Microwave-Engineered Symmetric Curcumin Derivatives.

Curcumin is a polyphenol of the Curcuma longa plant, which can be used for various medicinal purposes, such as inflammation and cancer treatment. In this context, two symmetric curcumin derivatives (D1-(1E,6E)-1,7-bis(4-acetamidophenyl)hepta-1,6-diene-3,5-dione and D2-p,p-dihydroxy di-cinnamoyl methane) were obtained by the microwave-based method and evaluated for their antitumoral effect on human cervix cancer in comparison with toxicity on non-tumoral cells, taking into account that they were predicted to act as apoptosis agonists or anti-inflammatory agents. The HeLa cell line was incubated

Acoustically-Activated Liposomal Nanocarriers to Mitigate the Side Effects of Conventional Chemotherapy with a Focus on Emulsion-Liposomes.

To improve currently available cancer treatments, nanomaterials are employed as smart drug delivery vehicles that can be engineered to locally target cancer cells and respond to stimuli. Nanocarriers can entrap chemotherapeutic drugs and deliver them to the diseased site, reducing the side effects associated with the systemic administration of conventional anticancer drugs. Upon accumulation in the tumor cells, the nanocarriers need to be potentiated to release their therapeutic cargo. Stimulation can be through endogenous or exogenous modalities, such as temperature, electromagnetic irradiati

Совпадение в полном тексте источника
… Thus, eLiposomes sequestered Dox, decreasing systemic toxicity and minimizing Dox-induced side effects such as cardiotoxicity. … Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment Curr. Cardiol. Rev. 2011 7 214 220 10.2174/157340311799960645 22758622 PMC3322439 26. Zhao L. Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes Sci. …

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study.

ObjectiveWe investigate safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma.MethodsWe retro-prospective analyzed 75 patients in three centers in Tuscany, 48 of whom had a clinically relevant comorbidity and 50 of whom were older than 65 years, treated with a median use in the fourth line of therapy. We assessed the efficacy based on the International Myeloma Working Group criteria.ResultsThe overall response rate was 60%. Median PFS was 10 months i

Совпадение в полном тексте источника
… In addition, we noticed that serious non‐hematological events were a minority of all recorded events (32%), with a small part of these related to the carfilzomib cardiotoxicity profile. … Molecular mechanism of carfilzomib‐induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133:710‐723. 14. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA‐ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. …

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Retrospective studies suggest that chimeric antigen receptor T-cell (CAR T) therapy may lead to cardiac injury, but this has not been assessed systematically or prospectively. In this prospective study of 40 patients who received CAR T, we systematically measured high-sensitivity troponin T (hsTropT) and N-terminal pro-B natriuretic peptide (NTproBNP) at baseline and on day 1, days 7, and 21 after CAR T. Biomarker elevations with respect to timepoint and cytokine release syndrome (CRS) status were examined using repeated measure analysis of variance. hsTropT did not differ with time or with th

Совпадение в полном тексте источника
… The mechanism by which CRS might cause cardiotoxicity has not yet been elucidated. CRS is known to upregulate interleukin-6 and plasminogen activator inhibitor and to cause vascular endothelial leakage [ 18 ]. … In a recent study of patients with CRS from CAR T therapy, none developed cardiotoxicity independent of developing CRS [ 19 ]. Interestingly, in our study, NTproBNP increased more in patients without than in patients with grade 2 CRS. …

Иммуноглобулин А лямбда, связанный с миеломой, легкий сердечный амилоидоз с постепенной сердечной недостаточностью с консервируемой фракцией выброса: отчет о мультимодальной съемке.

Участие в кардиологической деятельности является основным фактором, определяющим прогноз иммуноглобулиновой световой цепи (AL) амилоидоз, но может быть недооценено у пациентов с множественной миеломой (MM), особенно в тех случаях, когда отсутствуют классические электрокардиографические или сердечные магнитные резонансные характеристики. Таким образом, раннее признание зависит от интеграции сердечных биомаркеров и мультимодальных изображений в тех случаях, когда биопсия тканей или синтиграфическая подстилка непрактична.Резюме дела: A 74-year-old - у человека с иммуноглобулином Алямбда ММ и имму

Совпадение в полном тексте источника
… amyloidosis but is neither necessary nor sufficient for diagnosing AL amyloidosis. 1 , 6 In patients with MM, scintigraphy may be negative or misleading; thus, a negative scan cannot exclude AL, and positive uptake does not reliably confirm it. 3 , 6 Management priorities and chemotherapy-related cardiotoxicity … Similar diagnostic challenges of AL cardiac amyloidosis secondary to MM have also been described in previously published case reports and case series. 11-15 Alternative explanations, including hypertensive remodelling or chemotherapy-related cardiotoxicity, cannot be fully excluded, although integrated …

Cardiovascular Complications and Subclinical Myocardial Dysfunction in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Background: Cardiovascular complications are increasingly recognized in patients undergoing hematopoietic stem cell transplantation (HSCT). Early detection of subclinical myocardial dysfunction may improve risk stratification, and global longitudinal strain (GLS) is emerging as a sensitive marker of early cardiac impairment. Methods: We conducted a single-center observational cohort study including 518 adult patients undergoing autologous (n = 64) or allogeneic (n = 454) HSCT between 2004 and 2025. Baseline cardiovascular risk factors, transplant characteristics, and echocardiographic paramete

Совпадение в полном тексте источника
… In patients receiving potentially cardiotoxic therapies, strain abnormalities frequently precede reductions in left ventricular ejection fraction and may identify patients at higher risk for overt cardiotoxicity [ 13 , 14 ]. … Chemotherapy Related Cardiotoxicity Evaluation-A Contemporary Review with a Focus on Cardiac Imaging J. Clin. Med. 2024 13 3714 10.3390/jcm13133714 38999280 PMC11242267 13. Sławiński G. Hawryszko M. Liżewska-Springer A. Nabiałek-Trojanowska I. Lewicka E. …

Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential.

The growing number of cancer cases highlights the urgent need to develop new therapies based on effective molecules. Although anticancer activity remains a key element of oncological pharmacology, the importance of agents that support physiological functions and improve the quality of life of cancer patients is also recognised. Compounds that combine these two functions could represent a significant trend in oncology. Moreover, repurposing approved drugs for conditions beyond their original indications could be a promising strategy. An interesting example of this is synthetic flozins (SGLT2 in

Совпадение в полном тексте источника
… As of now, three ongoing clinical trials are showing SGLT2i as an intervention in assessing their role in the prevention of cardiotoxicity ( NCT06888505 , NCT06844669 , NCT05271162 ) [ 70 ]. … Cardiotoxicity of anticancer drugs: Molecular mechanisms, clinical management and innovative treatment Drug Des. Devel. Ther. 2024 18 4089 4116 10.2147/DDDT.S469331 PMC11404500 39286288 59. Matsubara T. Yokoi H. Yamada H. Yanagita M. …

Human-Induced Pluripotent Stem Cell Models for Amyloid Cardiomyopathy: From Mechanistic Insights to Therapeutic Discovery.

Amyloid cardiomyopathy (ACM), driven by transthyretin (TTR) and immunoglobulin light chain (LC) amyloid fibrils, remains a major clinical challenge due to limited mechanistic understanding and insufficient preclinical models. Human-induced pluripotent stem cells (iPSCs) have emerged as a transformative platform to model ACM, offering patient-specific and genetically controlled systems. In this review, we summarize recent advances in the use of iPSC-derived cardiomyocytes (iPSC-CMs) in both two-dimensional (2D) monolayer cultures and three-dimensional (3D) constructs-including spheroids, organo

Совпадение в полном тексте источника
… This enables mechanistic interrogation of mutation-specific pathogenicity and supports screening of candidate therapeutics aimed at mitigating cardiotoxic effects ( Figure 2 C). … Together, these studies support the use of cardiac spheroids as a physiologically relevant 3D model for both AL and ATTR, thus enabling sensitive and spatially resolved assessment of amyloid-induced cardiotoxicity. …

Cardiovascular disease and chimeric antigen receptor cellular therapy.

Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary personalized therapy that has significantly impacted the treatment of patients with hematologic malignancies refractory to other therapies. Cytokine release syndrome (CRS) is a major side effect of CAR T therapy that can occur in 70-90% of patients, with roughly 40% of patients at grade 2 or higher. CRS can cause an intense inflammatory state leading to cardiovascular complications, including troponin elevation, arrhythmias, hemodynamic instability, and depressed left ventricular systolic function. There are currently no stand

Совпадение в полном тексте источника
… Older age and prior cardiotoxic cancer therapy (i.e., anthracyclines, chest radiation) may also raise the risk of CV toxicity after treatment ( 68 ). … CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC CardioOncol. ( 2020 ) 2 : 97 – 109 . 10.1016/j.jaccao.2020.02.011 34396213 PMC8352125 61. Jamal FA Khaled SK . …

Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments.

Desmoid tumors (DTs) are rare, fibroblastic neoplasms characterized by locally aggressive behavior, unpredictable clinical trajectories, and a substantial impact on patient quality of life despite minimal metastatic potential. Although the underlying biology of DTs remains incompletely defined, associations with prior trauma, hormonal exposure, and aberrant Wnt/β-catenin signaling-including somatic CTNNB1 mutations and germline APC alterations seen in Familial Adenomatous Polyposis-have informed both historical and contemporary therapeutic approaches. Management strategies have evolved from su

Совпадение в полном тексте источника
… Regarding adverse effects, the study reports two patients, of the 35 who received anthracyclines, who developed cardiotoxicity [ 31 ]. … Although both patients had improvement in their symptoms with medical management, cardiotoxicity remains one of the key limiting variables in prescribing doxorubicin. …

Characteristics of patients with newly diagnosed hematological malignancies referred for echocardiography.

ObjectiveThe importance of cardio-hemato-oncology programs is increasing. The main aim of the study was to identify all coexisting cardiovascular disorders in patients with new hematological malignancies referred for echocardiography during baseline evaluation before anticancer therapy.Material and methodsThe study was based on 900 echocardiographic examinations performed within 12 months at the Institute of Hematology and Transfusion Medicine in Poland: 669 tests (74.3%) were dedicated to hemato-oncology patients at the different stages of cancer therapy, however almost a third of the tests (

Evidence-based exercises intervention in adults diagnosed with Lymphoma.

ObjectivesTo evaluate the efficacy of physical therapy or exercise intervention on quality of life (QOL), fatigue, sleep, and psychological and physical functioning in adults diagnosed with Lymphoma.MethodsA systematic literature search of the PubMed, CINAHL, Cochrane Library, and PEDro databases was carried out to identify articles published from March 2010 until December 2020. The risk of bias, methodological quality, and level of evidence was evaluated using the Physiotherapy Evidence Database (PEDro) checklist.ResultsOut of the 577 articles identified from the initial search, a total of 12

Совпадение в полном тексте источника
… | 11778 31 | Bone health or cardiotoxicity or cardio-toxicity or spine metastasis or impairments or fatigue or chronic fatigue or pain or quality of life or chemotherapy induced neuropathy | 1426700 32 | 6 and 20 and 31 | 996 33 | 32 filters: published in the last 10 years; humans; English; adult: 19 … Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant . Pediatr Blood Cancer 2017 ; 64 . 28453909 10.1002/pbc.26600 10. Husson O , Oerlemans S , Mols F , Schep G , Van De Poll-Franse LV. …

Stress cardiomyopathy in hospitalized patients with cancer: machine learning analysis by primary malignancy type.

AimsPrevious studies have shown that patients with stress (Takotsubo) cardiomyopathy (SC) and cancer have higher in-hospital mortality than patients with SC alone. No studies have examined outcomes in patients with active cancer and SC compared to patients with active cancer without SC. We aimed to assess the potential association between primary malignancy type and SC and their shared interaction with inpatient mortality.Methods and resultsWe analysed SC by primary malignancy type with propensity score adjusted multivariable regression and machine learning analysis using the 2016 United State

Совпадение в полном тексте источника
… A noteworthy finding in our study was that, despite all the related treatments known to cause physical and emotional stress and cardiotoxicity, the only malignancies significantly associated with developing SC were breast and lung cancer. … Anthracyclines and anti‐HER2 therapies for breast cancer are notorious for causing cardiotoxicity. …

The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.

BackgroundPrevious meta-analysis studies suggested that pegylated liposomal doxorubicin (PLD) may improve the survival rate of patients with recurrent ovarian cancer. The aim of the present meta-analysis, then, was to further update the role of PLD in the treatment of recurrent ovarian cancer.MethodsWe performed a literature search using the electronic databases Medicine, EMBASE, Web of Science, and the Cochrane Library to 27 July 2020. We only restricted the randomized clinical trials. Study-specific hazard ratios and 95% confidence interval (HR/95% CI) and risk ratios and 95% confidence inte

Совпадение в полном тексте источника
… Studies show that PLD reduced the incidence of cardiotoxicity five-to-six fold even at doses ≥500 mg/m 2 . … One study depicted no significant incidence of cardiotoxicity (as defined by 2D strain on 3D left-ventricular ejection fraction), even with high cumulative doses of PLD up to 2500 mg, and therefore long-term use appears safe [ 29 ]. …

Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study.

PURPOSE: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) heavily pretreated with anthracycline and taxanes. METHODS: In this single-arm, phase II study, patients with HER2-negative MBC previously treated with anthracycline and taxanes as second- to fifth chemotherapy received PLD (Duomeisu®, generic doxorubicin hydrochloride liposome) 40 mg/m2 every 4 weeks until disease progression, unacceptable toxicity, or completion of six cycles. Primary endpoint was progr

Совпадение в полном тексте источника
… Regarding cardiotoxicity, most patients (97.6%) had no significant decrease in LVEF during treatment, and only one patient experienced a decrease in LVEF from 70% at baseline to 62% after five cycles of PLD. … Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. …

Research progress on arsenic, arsenic-containing medicinal materials, and arsenic-containing preparations: clinical application, pharmacological effects, and toxicity.

Introduction: The toxicity of arsenic is widely recognized globally, mainly harming human health by polluting water, soil, and food. However, its formulations can also be used for the clinical treatment of diseases such as leukemia and tumors. Arsenic has been used as a drug in China for over 2,400 years, with examples such as the arsenic-containing drug realgar mentioned in Shennong's Herbal Classic. We have reviewed references on arsenic over the past thirty years and found that research has mainly focused on clinical, pharmacological, and toxicological aspects. Results and Discussion: The f

Совпадение в полном тексте источника
… Cardiotoxicity has also been found to be significant when ATO is used therapeutically ( Zhang, F. et al., 2018 ), and cardiotoxicity is mainly of two types: (sub)acute cardiotoxicity and chronic cardiotoxicity. … FIGURE 3 Arsenic-induced cardiotoxicity. …